mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Other tools focus on applying structured constraints to inputs, restricting outputs to predefined parameters, or using real-time monitoring mechanisms to identify and address vulnerabilities. These efforts aim to ensure that AI systems are designed with safety and ethical considerations at the forefront, particularly as their use becomes increasingly widespread in critical applications.
This process allows many recombinant proteins to be secreted as soluble, physiologically active forms into the culture medium. The technology required for genetic manipulation of Komagataella is similar to that of Saccharomyces cerevisiae, which is one of the most well-studied yeast model organisms. As a result, the experiment protocol and materials are easy to build for Komagataella.
Lots of love from Teddy RyderTheodore Ryder became a librarian in Hartford, Connecticut and lived a life without significant diabetes-related complications. He remained on friendly terms with Banting through regular correspondence until his death in 1941. Banting visited Theodore Ryder twice in the years following his treatment. The letters from Ryder to Banting are part of his estate and have been reproduced several times in medical history treatises on the medical history of diabetes. The collection of letters from Banting to Ryder has been in the holdings of the Thomas Fisher Library at the University of Toronto since 1999. In one of these letters, Banting wrote in December 1938, among other things:I shall always follow your career with interest and you will forgive me if I add, a little pride, because I shall always remember the difficult times we had in the early days of insulin. The outstanding thing I remember was your strength and fortitude in observing your diet and the manly way in which you stood up to the punishment of hypodermic injections. I am sure that you will be a success in life if you maintain the same spirit in meeting the rebuffs of the world.Theodore Ryder rose to prominence in the 1980s, as from this point onwards the length of time that he had lived with his illness and his state of health made him an exception even among long-term survivors of diabetes. The American Diabetes Society sells a coloring book for preschool children called “Teddy Ryder Rides Again” that aims to provide them with basic knowledge about the disease and its treatment.
=== EC 1.2.1 With NAD+ or NADP+ as acceptor === EC 1.2.1.1: deleted, replaced by EC 1.1.1.284, S-(hydroxymethyl)glutathione dehydrogenase and EC 4.4.1.22, S-(hydroxymethyl)glutathione synthase EC 1.2.1.2: Now EC 1.17.1.9, formate dehydrogenase EC 1.2.1.3: aldehyde dehydrogenase (NAD+) EC 1.2.1.4: aldehyde dehydrogenase (NADP+) EC 1.2.1.5: aldehyde dehydrogenase (NAD(P)+) EC 1.2.1.6: deleted (was benzaldehyde dehydrogenase) EC 1.2.1.7: benzaldehyde dehydrogenase (NADP+) EC 1.2.1.8: betaine-aldehyde dehydrogenase EC 1.2.1.9: glyceraldehyde-3-phosphate dehydrogenase (NADP+) EC 1.2.1.10: acetaldehyde dehydrogenase (acetylating) EC 1.2.1.11: aspartate-semialdehyde dehydrogenase EC 1.2.1.12: glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) EC 1.2.1.13: glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) EC 1.2.1.14: Now EC 1.1.1.205, IMP dehydrogenase EC 1.2.1.15: malonate-semialdehyde dehydrogenase EC 1.2.1.16: succinate-semialdehyde dehydrogenase [NAD(P)+] EC 1.2.1.17: glyoxylate dehydrogenase (acylating) EC 1.2.1.18: malonate-semialdehyde dehydrogenase (acetylating) EC 1.2.1.19: aminobutyraldehyde dehydrogenase EC 1.2.1.20: glutarate-semialdehyde dehydrogenase EC 1.2.1.21: glycolaldehyde dehydrogenase EC 1.2.1.22: lactaldehyde dehydrogenase EC 1.2.1.23: 2-oxoaldehyde dehydrogenase (NAD+) EC 1.2.1.24: succinate-semialdehyde dehydrogenase (NAD+) EC 1.2.1.25: branched-chain α-keto acid dehydrogenase system EC 1.2.1.26: 2,5-dioxovalerate dehydrogenase EC 1.2.1.27: methylmalonate-semialdehyde dehydrogenase (CoA-acylating) EC 1.2.1.28: benzaldehyde dehydrogenase (NAD+) EC 1.2.1.29: aryl-aldehyde dehydrogenase EC 1.2.1.30: aryl-aldehyde dehydrogenase (NADP+) EC 1.2.1.31: L-aminoadipate-semialdehyde dehydrogenase EC 1.2.1.32: aminomuconate-semialdehyde dehydrogenase EC 1.2.1.33: (R)-dehydropantoate dehydrogenase EC 1.2.1.34: Now EC 1.1.1.131, mannuronate reductase EC 1.2.1.35: Now EC 1.1.1.203, uronate dehydrogenase EC 1.2.1.36: retinal dehydrogenase EC 1.2.1.37: Now EC 1.17.1.4, xanthine dehydrogenase EC 1.2.1.38: N-acetyl-γ-glutamyl-phosphate reductase EC 1.2.1.39: phenylacetaldehyde dehydrogenase EC 1.2.1.40: part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.2.1.41: glutamate-5-semialdehyde dehydrogenase EC 1.2.1.42: hexadecanal dehydrogenase (acylating) EC 1.2.1.43: Now EC 1.17.1.10, formate dehydrogenase (NADP+) EC 1.2.1.44: cinnamoyl-CoA reductase EC 1.2.1.45: Now EC 1.1.1.312, 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.2.1.46: formaldehyde dehydrogenase EC 1.2.1.47: 4-trimethylammoniobutyraldehyde dehydrogenase EC 1.2.1.48: long-chain-aldehyde dehydrogenase EC 1.2.1.49: 2-oxoaldehyde dehydrogenase (NADP+) EC 1.2.1.50: long-chain-fatty-acyl-CoA reductase EC 1.2.1.51: pyruvate dehydrogenase (NADP+) EC 1.2.1.52: deleted 2025 (was oxoglutarate dehydrogenase (NADP+)) EC 1.2.1.53: 4-hydroxyphenylacetaldehyde dehydrogenase EC 1.2.1.54: γ-guanidinobutyraldehyde dehydrogenase EC 1.2.1.55: Now EC 1.1.1.279, (R)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.56: Now EC 1.1.1.280, (S)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.57: butanal dehydrogenase EC 1.2.1.58: phenylglyoxylate dehydrogenase (acylating) EC 1.2.1.59: glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) EC 1.2.1.60: 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.61: 4-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.62: 4-formylbenzenesulfonate dehydrogenase EC 1.2.1.63: 6-oxohexanoate dehydrogenase EC 1.2.1.64: 4-hydroxybenzaldehyde dehydrogenase (NAD+) EC 1.2.1.65: salicylaldehyde dehydrogenase EC 1.2.1.66: Now EC 1.1.1.306, S-(hydroxymethyl)mycothiol dehydrogenase EC 1.2.1.67: vanillin dehydrogenase EC 1.2.1.68: coniferyl-aldehyde dehydrogenase EC 1.2.1.69: fluoroacetaldehyde dehydrogenase EC 1.2.1.70: glutamyl-tRNA reductase EC 1.2.1.71: succinylglutamate-semialdehyde dehydrogenase EC 1.2.1.72: erythrose-4-phosphate dehydrogenase EC 1.2.1.73: sulfoacetaldehyde dehydrogenase EC 1.2.1.74: abieta-7,13-dien-18-al dehydrogenase EC 1.2.1.75: malonyl CoA reductase (malonate semialdehyde-forming) EC 1.2.1.76: succinate-semialdehyde dehydrogenase (acylating) EC 1.2.1.77: 3,4-dehydroadipyl-CoA semialdehyde dehydrogenase (NADP+) EC 1.2.1.78: 2-formylbenzoate dehydrogenase EC 1.2.1.79: succinate-semialdehyde dehydrogenase (NADP+) EC 1.2.1.80: long-chain acyl-[acyl-carrier-protein] reductase EC 1.2.1.81: sulfoacetaldehyde dehydrogenase (acylating) EC 1.2.1.82: β-apo-4′-carotenal oxygenase EC 1.2.1.83: 3-succinoylsemialdehyde-pyridine dehydrogenase EC 1.2.1.84: alcohol-forming fatty acyl-CoA reductase EC 1.2.1.85: 2-hydroxymuconate-6-semialdehyde dehydrogenase EC 1.2.1.86: geranial dehydrogenase EC 1.2.1.87: propanal dehydrogenase (CoA-propanoylating) EC 1.2.1.88: L-glutamate γ-semialdehyde dehydrogenase EC 1.2.1.89: D-glyceraldehyde dehydrogenase (NADP+) EC 1.2.1.90: glyceraldehyde-3-phosphate dehydrogenase [NAD(P)+] EC 1.2.1.91: 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.2.1.92: 3,6-anhydro-α-L-galactose dehydrogenase EC 1.2.1.93: formate dehydrogenase (NAD+, ferredoxin). Now EC 1.17.1.11, formate dehydrogenase (NAD+, ferredoxin) * EC 1.2.1.94: farnesal dehydrogenase EC 1.2.1.95: L-2-aminoadipate reductase EC 1.2.1.96: 4-hydroxybenzaldehyde dehydrogenase (++) EC 1.2.1.97: 3-sulfolactaldehyde dehydrogenase EC 1.2.1.98: 2-hydroxy-2-methylpropanal dehydrogenase EC 1.2.1.99: 4-(γ-glutamylamino)butanal dehydrogenase EC 1.2.1.100: 5-formyl-3-hydroxy-2-methylpyridine 4-carboxylic acid 5-dehydrogenase EC 1.2.1.101: L-tyrosine reductase EC 1.2.1.102: isopyridoxal dehydrogenase (5-pyridoxate-forming) EC 1.2.1.103: [amino-group carrier protein]-6-phospho-L-2-aminoadipate reductase EC 1.2.1.104: pyruvate dehydrogenase system EC 1.2.1.105: 2-oxoglutarate dehydrogenase system EC 1.2.1.106: [amino-group carrier protein]-5-phospho-L-glutamate reductase EC 1.2.1.107: glyceraldehyde-3-phosphate dehydrogenase (arsenate-transferring)
In 1981, the company was founded by two scientist/engineers from Hewlett Packard, Sam Eletr and André Marion based on technology developed by Leroy Hood and Marvin H. Caruthers. In 1982, Applied Biosystems released its first commercial instrument, the Model 470A Protein Sequencer. The machine enabled scientists to determine the order of amino acids within a purified protein, which in turn correlated with the protein's function. With 40 employees, the company, reported first-time revenue of US$402,000. In 1983, the company was led by its president and Chairman of the Board, Sam Eletr and Chief Operating Officer Andre Marion, the company doubled its number of employees to 80, and its stock went public on the NASDAQ exchange under the symbol ABIO, with revenues of US$5.9 million. A new product was a fluorescent molecular tag for immunodiagnostic assays. The company released its second commercial instrument, the Model 380A DNA Synthesizer, which made oligonucleotides, short DNA strands, for polymerase chain reaction (PCR), DNA sequencing, and gene identification. The two sequencer and synthesizer products allowed molecular biologists to clone genes by building oligonucleotides with the desired protein's DNA sequence. Automated DNA sequencing began at the California Institute of Technology, using fluorescent dyes, with Rights to the technology granted to Applied Biosystems. At CIT, Dr. Leroy Hood and Dr. Lloyd Smith, together pioneered those first DNA sequencing machines.
Sources: en.wikipedia.org
=== Business === Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates (PDC), peptides, and small molecule-based drugs. It is traded publicly on the Tokyo First Stock Exchange Market (the market capitalization is over JY 600 billions), which has many partnerships with pharmaceutical companies in worldwide. Suga is chair of the editorial board at RSC Chemical Biology and associate editor at Angewandte Chemie.
integral membrane protein (IMP) Also intrinsic membrane protein. Any of a class of membrane proteins which are permanently embedded within or attached to the cell membrane (as opposed to those which are attached only temporarily). Integral membrane proteins can be subclassified into integral polytopic proteins, which span the entirety of the membrane, and integral monotopic proteins, which adhere only to one side.
== Nixon's visit to Moscow == At the time of the Easter Offensive, Kissinger was deeply involved in planning for Nixon's visit to Moscow in May 1972. The offensive brought to the fore the differences between Nixon and Kissinger. Nixon threatened to cancel his summit with Leonid Brezhnev in Moscow if the Soviet Union did not force North Vietnam to end the Easter Offensive at once, saying: "Whatever else happens, we cannot lose this war. The summit isn't worth a damn if the price for it is losing in Vietnam". Nixon, in his instructions to Kissinger, stated that he viewed the relations with the Soviet Union through the prism of the Vietnam War, and if the Soviets were not prepared to help, Kissinger "should just pack up and come home". Kissinger, for his part, believed that Nixon was massively exaggerating Soviet influence in North Vietnam and no longer believed, if he ever did, in Nixon's "linkage" concept. Kissinger feared that Nixon was obsessed with Vietnam, and damaging relations with the Soviet Union over Vietnam would destabilize the international power balance by increasing American-Soviet tensions. On 20 April 1972, Kissinger arrived in Moscow without informing the U.S. ambassador Jacob D. Beam, and then went to have tea with Brezhnev in the Kremlin. Nixon, as usual when under stress, departed for a marathon drinking session with Rebozo at Camp David, and via Haig kept sending messages to Kissinger urging him to be tough with Brezhnev.
The fish is of low commercial value, giving off a pungent stench. Ciguatera poisoning may occur if the flesh is consumed. The adult fish's caudal spine is sharp, and is only out when the fish experiences excitement of some form. These fins can cut very deep into human skin and have been known to result in infections, mainly characterized by swelling and discoloration. Pain from such infections can last for long periods of time, sometimes for hours. Some species of the genus Acanthurus are even thought to possess poison glands on their caudal spines.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.